Myoridge completes out-license agreement with Avery Therapeutics
Myoridge Co. Ltd. (President: Naohiro Makita) has signed a license agreement with Avery
Therapeutics, Inc. (“Avery”), a company based in Arizona that develops regenerative medicine
products using iPS cell-derived cardiomyocytes. Myoridge provides to Avery a non-exclusive license
for the method of inducing differentiation of iPS cell-derived cardiomyocytes owned by Myoridge and
licensed from Kyoto University.
Please refer to the news release below in datail.